John Dubay, MD
Medical Oncology · Tuscaloosa, ALNPI 1033137518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for medical oncology clinicians in AL, where the typical reported total is $5,924.
Across 82 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$306
- Delcath Systems$235
- Caris MPI, Inc.$157
- E.r. Squibb & Sons, L.L.C.$112
- Novartis$80
- Johnson & Johnson$73
- plus $544 from 20 others
Across 137 payments — averaging $5509.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$408K
- Iovance Biotherapeutics, Inc.$167K
- Bristol Myers Squibb$55K
- AVEO Pharmaceuticals, Inc.$48K
- Pfizer$47K
- Regeneron$23K
- plus $8K from 1 others
What the payments were for
- Food & beverage$1,46497%
- Education$443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 18 | $306 |
| Delcath Systems | 1 | $235 |
| Caris MPI, Inc. | 13 | $157 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| Novartis | 5 | $80 |
| Johnson & Johnson | 4 | $73 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $69 |
| Pfizer | 4 | $50 |
| Bristol Myers Squibb | 3 | $48 |
| GSK | 2 | $44 |
| Gilead(2 entities) | 3 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Secura Bio, Inc. | 2 | $28 |
| Myriad Genetic Laboratories, Inc. | 1 | $27 |
| Iovance Biotherapeutics, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Amgen | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hepzato Kit$235
How this compares
$1,507 in reported general payments places this provider in the 15th percentile of 30 medical oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 29 | $464,842 |
| BraftoviEncorafenib | 13 | $189,189 |
| XtandiEnzalutamide | 13 | $174,607 |
| MektoviBinimetinib | 13 | $166,078 |
| Abiraterone Acetate | 59 | $144,330 |
| ErivedgeVismodegib | 11 | $138,105 |
| Lanreotide Acetate | 14 | $122,501 |
| XermeloTelotristat Etiprate | 12 | $117,260 |
| OrgovyxRelugolix | 13 | $33,718 |
| Fentanyl | 24 | $3,482 |
| Oxycodone Hcl | 56 | $1,059 |
| Hydrocortisone | 28 | $957 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 54 | $776 |
| Ondansetron OdtOndansetron | 17 | $545 |
| Levothyroxine Sodium | 34 | $462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $19 | $464,84229 claims |
| Astellas Pharma US IncXtandi | $16 | $174,60713 claims |
| Tersera Therapeutics LLCXermelo | $14 | $117,26012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 30 medical oncology providers in Alabama.
Other medical oncology in Tuscaloosa
- Susan BostickTuscaloosa$17K
- David HintonTuscaloosa$16K
- Ariel AnguianoTuscaloosa$5K
- Edgar PrasthoferTuscaloosa$834
- Ajay TadepalliTuscaloosa$177
- Joelle HamiltonHomewood$361K
- Syed Abbas AliJasper$51K
- Pranitha ProdduturvarMobile$33K
- Johnny NacillaCullman$23K
- Michael GarciaJasper$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.